Mirae Asset Global Investments Co. Ltd. Has $69,000 Position in Sarepta Therapeutics, Inc. $SRPT

Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 25.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,042 shares of the biotechnology company’s stock after acquiring an additional 819 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Sarepta Therapeutics were worth $69,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in SRPT. Byrne Asset Management LLC acquired a new position in Sarepta Therapeutics in the 1st quarter valued at $30,000. Center for Financial Planning Inc. acquired a new position in Sarepta Therapeutics in the 1st quarter valued at $31,000. Ancora Advisors LLC grew its holdings in Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 300 shares in the last quarter. Pandora Wealth Inc. acquired a new position in Sarepta Therapeutics in the 1st quarter valued at $45,000. Finally, Brooklyn Investment Group grew its holdings in Sarepta Therapeutics by 450.4% in the 1st quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 590 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Performance

SRPT opened at $22.11 on Monday. The firm has a market cap of $2.16 billion, a P/E ratio of -25.41 and a beta of 0.51. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $138.81. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. The business’s fifty day moving average is $19.11 and its 200-day moving average is $30.44.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $1.13. The company had revenue of $611.09 million for the quarter, compared to analyst estimates of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.Sarepta Therapeutics’s quarterly revenue was up 68.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.07 EPS. Sell-side analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on SRPT shares. Sanford C. Bernstein started coverage on Sarepta Therapeutics in a report on Tuesday, July 29th. They issued a “market perform” rating and a $13.00 price objective on the stock. BMO Capital Markets raised Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a report on Monday, September 22nd. Morgan Stanley upped their price objective on Sarepta Therapeutics from $15.00 to $20.00 and gave the company an “equal weight” rating in a report on Tuesday, July 29th. Leerink Partnrs lowered Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, July 18th. Finally, Citigroup assumed coverage on Sarepta Therapeutics in a report on Tuesday, July 22nd. They issued a “sell” rating on the stock. Eight analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and seven have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $34.42.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.